Silicon Valley Bank (SVB) provided the facility.
The company intends to use the funds to ramp up automation and to advance its drug development efforts, as well as purchase additional lab equipment for its new facility.
Led by Nick Conley, PhD (Chief Executive Officer and Co-Founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-Founder), Christina Tsai, PhD (Chief Science Officer & Co-Founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer), EpiBiome develop effective, sustainable FDA-approved therapies to combat infectious disease in humans and agriculture without the use of antibiotics.
In January, the company closed a $6m Series A funding round from Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group.
EpiBiome was a graduate from the inaugural class of Illumina Accelerator, a business accelerator that focuses on genomic companies.
FinSMEs
23/06/2016